Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 4 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 5 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
14 Sep 2019
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.

30-day readmission predicts mortality in hospitalized CDI patients with cirrhosis

01 Sep 2019

A third of Clostridium difficile infection (CDI) patients with cirrhosis have been readmitted in a span of 30 days primarily due to recurrent CDI, a recent study has found. In addition, there is a high rate of mortality linked to CDI in patients with cirrhosis, in which a poor prognosis is predicted by decompensation and 30-day readmission.

A total of 12,274 out of 366,283 (3.4 percent) patients hospitalized with CDI had cirrhosis. Of these, 7,741 (63.1 percent) were decompensated. Among CDI patients, those with vs without cirrhosis had higher 30-day readmission rates (33 percent vs 24 percent), index admission mortality (5 percent vs 2.5 percent) and calendar-year mortality (9 percent vs 4 percent).

The most common reasons for readmission were recurrent CDI (46 percent) and cirrhosis-related complications (34.6 percent). Patients with decompensated cirrhosis had a greater risk of readmission within 30 days than those with compensated cirrhosis (odds ratio [OR], 1.19, 95 percent CI, 1.03–1.36).

In multivariable analyses, index colectomy (OR, 6.50, 1.61–26.24) and decompensation (OR, 3.61, 2.49–5.23) predicted index admission mortality among patients with cirrhosis. Thirty-day readmission (OR, 3.71, 2.95–4.67) and decompensated cirrhosis (OR, 1.49, 1.17–1.89) were also independent predictors of calendar-year mortality.

“Reducing [recurrent] CDI-related readmissions may potentially improve these outcomes,” the investigators said.

This study used the Nationwide Readmission Database (2011–2014) to identify hospitalized patients with CDI and differentiate them according to the presence of cirrhosis. Baseline characteristics, surgical rates and outcomes were obtained. The primary outcomes were readmission and mortality rates.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 4 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 5 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
14 Sep 2019
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.